IRIS
GALLUZZO, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.119
EU - Europa 989
AS - Asia 707
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 4
AF - Africa 1
Totale 12.832
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.113
SG - Singapore 459
IE - Irlanda 231
IT - Italia 216
CN - Cina 151
DE - Germania 123
RU - Federazione Russa 120
UA - Ucraina 71
FR - Francia 55
GB - Regno Unito 48
FI - Finlandia 32
KR - Corea 30
SE - Svezia 29
IN - India 19
PL - Polonia 17
JP - Giappone 9
NL - Olanda 9
ES - Italia 8
CH - Svizzera 6
HK - Hong Kong 6
MY - Malesia 6
BE - Belgio 5
KG - Kirghizistan 5
TR - Turchia 5
AU - Australia 4
BR - Brasile 4
CA - Canada 4
PT - Portogallo 4
CL - Cile 3
CZ - Repubblica Ceca 3
EU - Europa 3
GR - Grecia 3
PK - Pakistan 3
RO - Romania 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AT - Austria 2
BD - Bangladesh 2
IR - Iran 2
MX - Messico 2
SI - Slovenia 2
UZ - Uzbekistan 2
AD - Andorra 1
AZ - Azerbaigian 1
IL - Israele 1
KZ - Kazakistan 1
MA - Marocco 1
MN - Mongolia 1
NO - Norvegia 1
TH - Thailandia 1
Totale 12.832
Salva come PNG Salva come JPEG
Città #
Wilmington 3.181
Houston 2.931
Woodbridge 1.606
Fairfield 687
Ashburn 416
Singapore 388
Seattle 330
Chandler 302
Cambridge 255
Dublin 212
Ann Arbor 191
Medford 151
Santa Clara 94
Dearborn 93
Lawrence 72
Beijing 63
Rome 61
San Diego 53
Jacksonville 43
Munich 34
Council Bluffs 32
Moscow 30
Del Norte 21
Zhengzhou 20
Menlo Park 18
London 17
Seoul 17
Perugia 15
Redwood City 15
Helsinki 14
Esslingen am Neckar 13
Kraków 13
Salt Lake City 13
Falls Church 10
New York 9
Pune 9
Saint Petersburg 9
Shanghai 9
Milan 8
Engelhard 7
Los Angeles 7
Nuremberg 7
Boardman 6
Guangzhou 6
Guiyang 6
Hong Kong 6
Kilburn 6
Norwalk 6
Brussels 5
Dongguan 5
Lappeenranta 5
Mountain View 5
Nanchang 5
Nanjing 5
Putrajaya 5
Turin 5
Bologna 4
Islington 4
Porto 4
Renton 4
Sedico 4
Warsaw 4
Bari 3
Brno 3
Chengdu 3
Chicago 3
Coushatta 3
Detroit 3
Espoo 3
Hefei 3
Hyderabad 3
Iesi 3
Jinan 3
Lahore 3
Lausanne 3
St. George 3
Washington 3
Ōtsu 3
Aprilia 2
Chions 2
Cinisello Balsamo 2
Clearwater 2
Frankfurt am Main 2
Frosinone 2
General Escobedo 2
Jinhua 2
Lucca 2
Madrid 2
Melbourne 2
Monte Vista 2
Mumbai 2
Nanning 2
Naples 2
Osaka 2
Palermo 2
Phoenix 2
Piombino Dese 2
San Jose 2
Senigallia 2
Sesto San Giovanni 2
Totale 11.668
Salva come PNG Salva come JPEG
Nome #
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 447
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 391
Tildrakizumab for treating psoriasis 387
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 385
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 371
Brodalumab for the treatment of psoriasis 368
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 367
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 362
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 360
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 359
Tofacitinib for the treatment of psoriasis 350
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 342
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 333
New insight into the pathogenesis of nail psoriasis and overview of treatment strategies 332
A safety evaluation of guselkumab for the treatment of psoriasis 311
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 303
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. 301
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 296
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 280
Photo-recall cutaneous reaction to gemcitabine 272
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 272
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 269
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 268
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 252
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 246
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 241
Pharmacotherapeutic management of psoriasis in adolescents and children 229
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study 222
Skin immunity and its dysregulation in psoriasis 222
Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy 218
Successful treatment of psoriatic crumbly nails with ustekinumab 212
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 207
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 201
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 192
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 171
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 166
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 163
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers 154
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 140
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 111
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 105
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 99
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 86
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 82
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 73
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 73
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 71
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 71
Italian guidelines in diagnosis and treatment of alopecia areata 70
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 69
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 67
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 66
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 61
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 60
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 54
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 53
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 52
Linear psoriasis following the typical distribution of the sciatic nerve 49
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 45
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts 44
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 43
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 42
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 41
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients 39
The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis 39
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 38
successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: a case series 37
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) 34
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 34
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 33
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study 33
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study 32
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks 31
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis 30
Potential role of HLA-Cw6 in clinical response to anti-tumour necrosis factor alpha and t-cell targeting agents in psoriasis patients 29
Myasthenia gravis associated with muscle-specific kinase antibodies in a patient treated with interleukin-17 inhibitor 27
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents 26
Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab 25
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry 25
Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis 24
Quality of life and psychological impact in patients with atopic dermatitis 24
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 23
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study 23
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS) 23
HLA-C*06:02 allele can influence clinical efficacy of certolizumab pegol? 23
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy 22
Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab 21
Anti-Herpes zoster vaccination in patients with dermatologic diseases: a position statement from the Italian SIDeMaST group of sexually transmitted, infectious and tropical diseases 21
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement 19
letter in response to the case report: “recalcitrant generalized granuloma annulare treated successfully with dupilumab” 16
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks 15
Long-Term Effectiveness of Brodalumab for the Treatment of Moderate-To-Severe Psoriasis: A Real-Life Multicenter Study of Up to 3 Years in a Real-Life Italian Cohort 12
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study 12
Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series 11
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study 11
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study 9
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study 9
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis 8
Dupilumab-associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case report 8
Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice 8
Totale 13.403
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.364
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.364
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.901 0 0 0 0 367 404 346 349 484 391 307 253
2020/20213.054 313 305 308 319 407 426 347 303 61 161 75 29
2021/2022861 46 69 81 14 31 35 140 34 60 52 73 226
2022/2023807 101 81 69 61 55 207 68 32 57 22 30 24
2023/2024565 33 6 15 16 45 80 93 51 3 40 120 63
2024/20251.076 101 412 246 278 39 0 0 0 0 0 0 0
Totale 13.445